PRODIGEST

Their core work

PRODIGEST is a Belgian biotech SME specializing in gut microbiome research, preclinical disease models, and translational biology for digestive and infectious diseases. Their work spans two distinct but connected domains: developing siRNA-based nanotherapies targeting Janus kinase pathways for inflammatory bowel diseases, and characterizing the complex interplay between fungi (primarily Candida), the human microbiota, and host immunity in the context of fungal infections. They contribute preclinical expertise — including ex vivo infection models, omics profiling, and animal models — to large European research consortia. Based in Gent-Zwijnaarde, Belgium, a recognized life sciences hub, PRODIGEST operates at the interface of academic-grade research and industrial translation.

What they specialise in

How they've shifted over time

In their early H2020 work (2017–2019, NEW DEAL), PRODIGEST was focused squarely on therapeutic engineering: siRNA delivery, nanoparticle formulation, colon targeting, and the JAK signaling pathway in IBD — a technology-heavy, translational agenda. By 2019, with FunHoMic, their focus shifted toward systems-level biology: fungal ecology, host immunity, and microbiota dynamics studied through omics and infection models rather than drug formulation. This suggests a broadening from "how do we deliver a therapeutic to the gut?" toward "how does the gut's microbial ecosystem drive disease?" — a shift from engineering toward mechanistic understanding.

PRODIGEST appears to be evolving from targeted drug delivery into broader microbiome systems research, positioning themselves for consortia working on infection, dysbiosis, and host-immune regulation — a growth area in EU Horizon funding.

How they like to work

PRODIGEST has participated exclusively as a consortium partner — never as coordinator — across both of their H2020 projects. Despite only two projects, they have engaged with 29 unique partners across 7 countries, which indicates they join large, multi-partner research consortia where they provide specialist expertise rather than organizational leadership. This profile suggests they are a reliable niche contributor: organizations building consortia around gut health, microbiome, or translational therapeutics would bring PRODIGEST in for their preclinical capabilities, not to manage the consortium.

PRODIGEST has built a network of 29 unique partners across 7 countries from just two projects, indicating they participate in broad, international research consortia. Their network spans multiple European countries, consistent with the typical academic-industrial composition of RIA and MSCA-ITN projects.

What sets them apart

PRODIGEST occupies a rare niche as a private SME with deep expertise in both gut therapeutic delivery and fungal-microbiome biology — two areas that are increasingly converging in the context of post-antibiotic dysbiosis and mucosal immunity. Most organizations in this space are academic; PRODIGEST brings an industry perspective with a mandate for clinical translation and scale-up, as explicitly flagged in NEW DEAL. For consortium builders, this makes them a valuable bridge between basic microbiome science and practical therapeutic development.

Highlights from their portfolio

• NEW DEAL
  Their largest project (EUR 463,344), combining siRNA therapeutics with nanoparticle engineering for colon-targeted IBD treatment — a technically ambitious drug delivery challenge with clear clinical relevance.
• FunHoMic
  An MSCA-ITN training network focused on the underexplored fungal component of the human microbiome, demonstrating PRODIGEST's ability to contribute to doctoral training consortia in emerging biomedical fields.